Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

NCT04454905 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: Camrelizumab
DRUG: Apatinib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]